HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized insights, has announced a partnership with HeartNexus Inc., a network of board-certified cardiologists specializing in cardiac test interpretation, peer consultations, and telemedicine visits. The collaboration enables HeartBeam to offer 24/7 cardiology reader services for patients experiencing cardiac symptoms outside traditional care settings.
Using HeartBeam’s patented 3D technology, patients can capture a 30-second, cable-free ECG recording anytime symptoms occur, transmitting the data to HeartNexus cardiologists for immediate interpretation. This real-time feedback loop aims to accelerate diagnosis and treatment for conditions such as arrhythmias and other cardiac events. The full press release is available here.
“Working with HeartNexus accelerates our mission to make medical-grade cardiac monitoring accessible beyond the walls of a medical facility,” said Robert Eno, CEO of HeartBeam. The partnership expands HeartBeam’s ecosystem with real-time cardiology feedback and future integration of AI wellness and wearable features.
HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software is currently under FDA review. The company holds over 20 issued patents related to its technology. By partnering with HeartNexus, HeartBeam aims to provide patients with immediate access to specialist interpretation, potentially reducing delays in care for those experiencing symptoms like chest pain or palpitations.
The collaboration highlights the growing trend of remote patient monitoring and telecardiology. For investors and healthcare providers, this development signals HeartBeam’s commitment to expanding its commercial offerings beyond device sales to include integrated services. More updates on HeartBeam are available in their newsroom.
HeartBeam is dedicated to transforming the detection and monitoring of critical cardiac conditions. The company is creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility.
